论文信息 - HLA-A02:01–Restricted Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP11/12 Preferentially Recall Polyfunctional Effector Memory CD8+ T Cells from Seropositive Asymptomatic Individuals and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpes

HLA-A02:01–Restricted Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP11/12 Preferentially Recall Polyfunctional Effector Memory CD8+ T Cells from Seropositive Asymptomatic Individuals and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpes

The HSV type 1 tegument virion phosphoprotein (VP) 11/12 (VP11/12) is a major Ag targeted by CD8+ T cells from HSV-seropositive individuals. However, whether and which VP11/12 epitope–specific CD8+ T cells play a role in the “natural” protection seen in seropositive healthy asymptomatic (ASYMP) individuals (who have never had clinical herpes disease) remain to be determined. In this study, we used multiple prediction computer-assisted algorithms to identify 10 potential HLA-A*02:01–restricted CD8+ T cell epitopes from the 718-aa sequence of VP11/12. Three of 10 epitopes exhibited high-to-moderate binding affinity to HLA-A*02:01 molecules. In 10 sequentially studied HLA-A*02:01–positive and HSV-1–seropositive ASYMP individuals, the most frequent, robust, and polyfunctional effector CD8+ T cell responses, as assessed by a combination of tetramer frequency, granzyme B, granzyme K, perforin, CD107a/b cytotoxic degranulation, IFN-γ, and multiplex cytokines assays, were predominantly directed against three epitopes: VP11/1266–74, VP11/12220–228, and VP11/12702–710. Interestingly, ASYMP individuals had a significantly higher proportion of CD45RAlowCCR7lowCD44highCD62LlowCD27lowCD28lowCD8+ effector memory CD8+ T cells (TEMs) specific to the three epitopes, compared with symptomatic individuals (with a history of numerous episodes of recurrent ocular herpetic disease). Moreover, immunization of HLA-A*02:01 transgenic mice with the three ASYMP CD8+ TEM cell epitopes induced robust and polyfunctional epitope-specific CD8+ TEM cells that were associated with a strong protective immunity against ocular herpes infection and disease. Our findings outline phenotypic and functional features of protective HSV-specific CD8+ T cells that should guide the development of an effective T cell–based herpes vaccine.

[1] Pamela G. Guren,et al. Candidates , 1982 .

[2] L. Szekely,et al. Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay , 1994, European journal of immunology.

[3] L. BenMohamed,et al. A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. , 1996, Journal of immunology.

[4] W. Leong,et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. , 1999, The New England journal of medicine.

[5] Rachael Keating,et al. The Cytotoxic T-Cell Response to Herpes Simplex Virus Type 1 Infection of C57BL/6 Mice Is Almost Entirely Directed against a Single Immunodominant Determinant , 1999, Journal of Virology.

[6] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[7] L. BenMohamed,et al. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. , 2000, Vaccine.

[8] Melanoma antigens recognised by CD8+ and CD4+ T cells. , 2000, Forum.

[9] Stork Wj,et al. Melanoma antigens recognised by CD8+ and CD4+ T cells. , 2000 .

[10] L. BenMohamed,et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. , 2000, Human immunology.

[11] L. BenMohamed,et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3 , 2000, Nature Medicine.

[12] Ferry Ossendorp,et al. Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis , 2001, The Journal of experimental medicine.

[13] A Sette,et al. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. , 2001, Human immunology.

[14] M. Gavin,et al. CD8 CTL from Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells1 , 2001, The Journal of Immunology.

[15] C. Rinaldo,et al. Identification of an HLA A*0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. , 2002, Blood.

[16] J Alexander,et al. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. , 2002, Tissue antigens.

[17] L. BenMohamed,et al. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses , 2002, Immunology.

[18] F. Aoki,et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. , 2002, The New England journal of medicine.

[19] A. Nesburn,et al. Lipopeptide vaccines--yesterday, today, and tomorrow. , 2002, The Lancet. Infectious diseases.

[20] L. BenMohamed,et al. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant , 2002, European journal of immunology.

[21] E. Erbelding. Glycoprotein D-adjuvant vaccine to prevent genital herpes. , 2003, Current infectious disease reports.

[22] R. Koup,et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[23] A. Wald,et al. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24] Mario Roederer,et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells , 2003, Nature Medicine.

[25] L. BenMohamed,et al. Lipopeptide epitopes extended by an Nϵ‐palmitoyl‐lysine moiety increase uptake and maturation of dendritic cells through a Toll‐like receptor‐2 pathway and trigger a Th1‐dependent protective immunity , 2004, European journal of immunology.

[26] A. Sette,et al. Recognition of Variant HIV-1 Epitopes from Diverse Viral Subtypes by Vaccine-Induced CTL1 , 2004, The Journal of Immunology.

[27] F. Celada,et al. CD8 memory T cells: cross-reactivity and heterologous immunity , 2004, Seminars in Immunology.

[28] I. Pastan,et al. Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells , 2004, Cancer Research.

[29] H. Volk,et al. Random Screening of Proteins for HLA-A*0201-Binding Nine-Amino Acid Peptides Is Not Sufficient for Identifying CD8 T Cell Epitopes Recognized in the Context of HLA-A*02011 , 2004, The Journal of Immunology.

[30] A. Nesburn,et al. Th-Cytotoxic T-Lymphocyte Chimeric Epitopes Extended by Nε-Palmitoyl Lysines Induce Herpes Simplex Virus Type 1-Specific Effector CD8+ Tc1 Responses and Protect against Ocular Infection , 2005, Journal of Virology.

[31] E. Castelli,et al. Typing class I HLA-A gene using a nested PCR-RFLP procedure. , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[32] E. Delwart,et al. Human Immunodeficiency Virus Mutations during the First Month of Infection Are Preferentially Found in Known Cytotoxic T-Lymphocyte Epitopes , 2005, Journal of Virology.

[33] Y. Naumov,et al. Memory of mice and men: CD8+ T‐cell cross‐reactivity and heterologous immunity , 2006, Immunological reviews.

[34] Barbara S. Stewart,et al. Identification of Protective Lassa Virus Epitopes That Are Restricted by HLA-A2 , 2006, Journal of Virology.

[35] E. Wherry,et al. Cutting Edge: IL-12 Inversely Regulates T-bet and Eomesodermin Expression during Pathogen-Induced CD8+ T Cell Differentiation1 , 2006, The Journal of Immunology.

[36] W. Heath,et al. CTL response compensation for the loss of an immunodominant class I‐restricted HSV‐1 determinant , 2006, Immunology and cell biology.

[37] A. Meier,et al. Diversity of the CD8+ T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes , 2006, Journal of Virology.

[38] A. Nesburn,et al. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. , 2006, The ocular surface.

[39] A. Nesburn,et al. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. , 2007, Investigative ophthalmology & visual science.

[40] Alan D. Roberts,et al. Activation phenotype, rather than central– or effector–memory phenotype, predicts the recall efficacy of memory CD8+ T cells , 2007, The Journal of experimental medicine.

[41] P. Terasaki,et al. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. , 2007, Human immunology.

[42] Tomer Hertz,et al. Identifying HLA supertypes by learning distance functions , 2007, Bioinform..

[43] E. Wherry,et al. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells , 2007, The Journal of experimental medicine.